Skip to main content

Abrysvo

Pronunciation: uh-breez-voh
Generic name: respiratory syncytial virus vaccineRSVpreFa/preFb-recombinant ]
Dosage form: Act-O-Vial for reconstitution (0.5 mL), vial and prefilled syringe (0.5 mL), vial and vial (0.5 mL)
Drug class: Viral vaccines

Medically reviewed by Carmen Pope, BPharm. Last updated on Jun 19, 2025.

What is Abrysvo?

Abrysvo is a vaccine used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD, lung infections) in pregnant women (32 through 36 weeks of gestation), adults 60 years and older, and adults aged 18 through 59 years at increased risk for LRTD caused by RSV. It is administered as a single intramuscular (IM) injection.

Abrysvo works by stimulating the immune system to produce antibodies against RSV's prefusion F protein, preventing respiratory disease. When given to pregnant women, these antibodies cross the placenta, providing passive immunity that protects newborns under 6 months from severe RSV infections. Abrysvo belongs to the drug class called RSV vaccines.

Abrysvo first gained FDA approval on May 31, 2023, for adults aged 60 and older. This approval was extended twice to include pregnant women and adults aged 18 through 59. Approvals were based on positive results from three clinical trials:

FDA approvals and uses

Abrysvo is a vaccine approved for active immunization of:

Side effects

The most common side effects of Abrysvo in pregnant women are:

The most common side effects of Abrysvo in adults 60 and older are:

The most common side effects of Abrysvo in adults aged 18 through 59 are:

Serious side effects and warnings

Abrysvo may cause the following serious side effects:

People who are immunocompromised, including those receiving immunosuppressive therapy, may have a diminished immune response to vaccines.

Vaccination with Abrysvo may not protect everybody who receives it.

Abrysvo is not approved for use in children.

These are not all the side effects of Abrysvo. Report all side effects to your healthcare provider or to the Vaccine Adverse Event Reporting System at 1-800-822-7967 and www.vaers.hhs.gov.

Before receiving

Do not receive an Abrysvo vaccine if you have a history of severe allergic reactions (such as anaphylaxis) to RSV vaccines, Abrysvo, or any of its inactive ingredients.

Before receiving Abrysvo tell your healthcare provider about all your medical conditions, including if you:

How do I receive Abrysvo?

Abrysvo is given by intramuscular injection, usually into the deltoid muscle of the upper arm.

Abrysvo is given to pregnant women from 32 weeks through 36 weeks gestation.

Dosing information

Dose of Abrysvo for pregnant women (32-36 weeks) and adults 18 years and older

Abrysvo ingredients

Active ingredients: 120 mcg of RSV stabilized perfusion F proteins (60 mcg RSV preF A and 60 mcg RSV preF B) per 0.5 mL.

Inactive ingredients: 0.11 mg tromethamine, 1.04 mg tromethamine hydrochloride, 11.3 mg sucrose, 22.5 mg mannitol, 0.08 mg polysorbate 80, and 1.1 mg sodium chloride per 0.5 mL.

Contains no preservatives.

The Act-O-Vial stoppers, vial stoppers and tip cap and rubber plunger of the prefilled syringe are not made with natural rubber latex.

Who makes Abrysvo?

Abrysvo is manufactured by Pfizer Inc. and distributed by Pfizer Labs, located in New York, NY 10001.

Abrysvo Biosimilars

Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.

Reference products

These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There is 1 for Abrysvo.

Abrysvo (Respiratory Syncytial Virus Vaccine) - Pfizer Inc.
Formulation type Strength
Single-Dose Vial 120 mcg

Popular FAQ

What is the difference between Arexvy and Abrysvo?

Arexvy and Abrysvo are both RSV vaccines that are approved for use in adults over the age of 60 to reduce their risk of developing lower respiratory tract disease (LRTD). They are also approved for adults aged 50 through 59 years (Arexvy) or aged 18 through 59 (Abrysvo) with certain chronic medical conditions (such as chronic pulmonary disease, chronic cardiovascular disease, diabetes, chronic kidney or liver disease) that put them at increased risk of LRTD caused by RSV. Abrysvo is also approved for use in pregnant women between 32 through 36 weeks gestation, to protect infants against LRTD from the moment they are born until they are 6 months of age. Arexvy is made by GSK and was approved on May 3, 2023; the first RSV vaccine to be approved for older adults. Abrysvo is made by Pfizer and was approved on May 31, 2023; the second RSV vaccine to be approved for older adults. Continue reading

What are the symptoms of RSV(respiratory syncytial virus)

RSV symptoms are runny nose, sore throat, stuffy nose, cough wheezing, headache, and fever for adults and RSV symptoms in the young include decreased activity, irritability, and breathing difficulties.

Continue reading

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.